Prevalence of Oral Findings in Egyptian Patients Diagnosed With Familial Mediterranean Fever

Prevalence of Oral Findings in Egyptian Patients Diagnosed With Familial Mediterranean Fever: A Hospital-Based Cross-sectional Study

This is an observational descriptive cross-sectional study will be performed at the Collagen Diseases Clinic, Abu Elreesh Japanese Children's Hospital, Cairo, Egypt. This study aims to Investigate and assess the prevalence of oral findings or lesions in Egyptian patients diagnosed with FMF

Study Overview

• Status: Not yet recruiting
• Conditions: Familial Mediterranean Fever (FMF ) and Oral Findings

Detailed Description

Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease and the most common of the periodic fever syndromes. FMF patients usually present with recurrent episodes of fever. They also suffer from abdominal, chest and joint pain due to serositis. Patients may present with erysipelas, amyloidosis, and rarely, ophthalmic manifestations. The oral cavity and related facial structures may also be affected. Oral lesions such as: recurrent oral ulcers, macroglossia and high arched palate. The prevalence of oral findings in FMF remains variable and underexplored. An accurate examination is required for the early identification of FMF cases. Diagnostic delay is common in FMF and complicated by incomplete clinical presentation and overlap in symptoms with other diseases. So, Recognizing other signs and symptoms could be incorporated into diagnostic criteria of FMF for early diagnosis and treatment with improvement of quality of life. This study will be performed at the Collagen Diseases Clinic, Abu Elreesh Japanese Children's Hospital, Cairo, Egypt. Egyptian children aged 6 to 15 years, with a confirmed diagnosis of FMF will be enrolled and recruited consecutively either at their initial diagnosis or follow-up visits. On the other hand, Children with other systemic diseases not related to FMF, children who are unable to cooperate or refuse to participate will be excluded from the study. During this visit, data will be collected through clinical oral examination using a standardized dental chart, along with a review of their medical records. The oral findings will be reported as binary data (yes / no). Moreover, documenting such oral findings could provide an important baseline for identifying FMF-associated anomalies in the population.

• Study Type: Observational
• Enrollment (Estimated): 359

Contacts and Locations

• Study Contact: Name: Amr Mahmoud Almorsy, MSc candidate; Phone Number: 01060964113 01014346192; Email: amr.almorsy@dentistry.cu.edu.eg
• Study Contact Backup: Name: Noha Adel Ibrahim, Lecturer; Phone Number: 01014346192 01001381954; Email: noha.adel@dentistry@cu.edu.eg

Study Locations

• Egypt
  • Cairo, Egypt
    • Collagen Diseases Clinic, Abu Elreesh Japanese Children's Hospital
    • Contact: Amr Mahmoud Alshafaey, MSc student; Phone Number: 01060964113 01014346192; Email: amr.almorsy@dentistry.cu.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Egyptian children aged 6 to 15 years, with a confirmed diagnosis of Familial Mediterranean Fever (FMF), attending the Collagen Diseases Clinic at Abu Elreesh Japanese Children's Hospital will be enrolled and recruited consecutively at a one point in time.

Description

Inclusion Criteria:

• Egyptian children aged 6 to 15 years
• Children with a confirmed diagnosis of Familial Mediterranean Fever (FMF)
• Children attending the Collagen Diseases Clinic at Abu Elreesh Japanese Children's Hospital.

Exclusion Criteria:

• Children with other systemic diseases not related to FMF
• Children who are unable to cooperate or refuse to participate

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Egyptian children with FMF; Egyptian children aged 6 to 15 years, with a confirmed diagnosis of Familial Mediterranean Fever (FMF), attending the Collagen Diseases Clinic at Abu Elreesh Japanese Children's Hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of Oral Findings in Egyptian patients Diagnosed with Familial Mediterranean Fever	The data will be collected through clinical oral examination using a standardized dental chart, along with a review of their medical records. The oral findings including high-arched palate, enamel defects, macroglossia, recurrent oral ulcers, and short philtrum will be reported as binary data (yes / no). Binary data such as prevalence of oral manifestations will be reported as a proportion.	At enrollment ( single cross-sectional visit)

Collaborators and Investigators

• Sponsor: Cairo University
• Investigators: Principal Investigator: Fat'heya Mohamed Zahran, Professor, Cairo University; Study Chair: noha adel ibrahim, lecturer, Cairo University; Study Chair: Hend mohamed abu shaday, assistant professor, Cairo University

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): October 30, 2026
• Study Completion (Estimated): July 30, 2027

Study Registration Dates

• First Submitted: September 23, 2025
• First Submitted That Met QC Criteria: November 21, 2025
• First Posted (Actual): November 25, 2025

Study Record Updates

• Last Update Posted (Actual): November 25, 2025
• Last Update Submitted That Met QC Criteria: November 21, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: FMF , Oral lesions
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Hereditary Autoinflammatory Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Familial Mediterranean Fever
• Other Study ID Numbers: OMED 2-1-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No